Seeking Alpha

In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that...

In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that its Abraxane treatment for advanced pancreatic cancer lengthened the survival of patients in a Phase III study. Pancreatic cancer could add up to $1B in sales of Abraxane, which is already approved to treat breast and lung tumors.
Comments (1)
  • TruffelPig
    , contributor
    Comments (4093) | Send Message
     
    Great news for patients of this terrible disease. There were many anekdotal rumors on cancer web sites on the efficiency of Abraxene in pancreatic cancer. The mechanism involves targeted delivery and thus the compatibility of the drug is much better than of the taxol.
    12 Nov 2012, 08:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs